Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Unicycive Therapeutics, Inc. - Common Stock (NQ: UNCY )

0.6099 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Unicycive Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Unicycive: This Biotech Company Receives Promising Results From New Trial
Unicycive: This Biotech Company Receives Promising Results From New Trial 
Via News Direct
Unicycive: This Biotech Company Receives Promising Results From New Trial
Unicycive Therapeutics Inc. (NASDAQ: UNCY) is a biotechnology company developing drug candidates currently focused on kidney disease. The innovative treatments may have vast potential outside of the... 
Via Benzinga
Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Therapeutics' Geographic Atrophy Candidate Shows Improved Contrast Vision In Animal Studies
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings
Data support UNI-494’s potential to treat acute kidney disease and underscore the phosphate binding benefits of Renazorb as a potential treatment for hyperphosphatemia 
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023
Growing body of clinical evidence support the potential of Renazorb and UNI-494 to effectively treat hyperphosphatemia and acute kidney disease, respectively 
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket
Gainers 
Via Benzinga
Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session
Gainers Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares jumped 121% to $0.4428 after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the... 
Via Benzinga
Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Cal-Maine Foods Shares Are Trading Lower; Here Are 24 Stocks Moving Premarket
Gainers Quotient Limited (NASDAQ: QTNT) shares rose 125% to $0.54 in pre-market trading after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the... 
Via Benzinga
Nasdaq Down 100 Points; Kala Pharmaceuticals Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 100 points on Wednesday. 
Via Benzinga
Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday's Mid-Day Session
Gainers Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Dow Tumbles 150 Points; Crude Oil Falls Sharply
U.S. stocks turned lower midway through trading, with the Dow Jones dropping around 150 points on Wednesday. 
Via Benzinga
Unicycive Shares Jump As Renazorb Achieves Primary Endpoint In Bioequivalence Study
Via Benzinga
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom
Expects to dose patients in first-in-human Phase 1 study with UNI-494 in first quarter 2023 
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Therapeutics, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
Planned Government Move To Expand Access To Drugs For End-Stage Renal Disease Patients Could Shine The Spotlight On Unicycive
In the U.S., reimbursement of dialysis expenses by the Centers for Medicare & Medicaid Services (CMS) is done using a prospective payment system (PPS) which enables the payout of a predetermined amount... 
Via Benzinga
Unicycive to Participate in Upcoming Investor Conferences
Highlights Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial Dysfunction 
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Announces Third Quarter Financial Results and Provides Business Update
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB™ (lanthanum dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on Dialysis
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers 
Via Benzinga
Unicycive to Showcase Pipeline of Innovative Product Candidates at American Society of Nephrology’s Kidney Week 2022
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.